Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advised NAVEX Global in connection with its acquisition of WhistleB Whistleblowing Centre AB
Mandate

Vinge advised NAVEX Global in connection with its acquisition of WhistleB Whistleblowing Centre AB

December 13, 2019 Capital Markets and Public M&A

Vinge has advised the risk and compliance software company NAVEX Global in connection with its acquisition of WhistleB Whistleblowing Centre AB, a company which offers an integrated whistleblowing case management system with reporting options in over 60 languages used by customers in more than 150 countries.

Vinge’s team consisted of, among others, Jonas Bergström, Linda Sengul, Desirée Sjöblom and Christina Odengran (M&A), Mathilda Persson and Lisa Hörnqvist (Commercial Agreements and IT), Malin Malm Waerme and Arvid Axelryd (IP), Sara Strandberg (Employment), Mia Falk (Compliance), Anna Grigorian (EU and Competition) and the VDR-assistant Nathalie Hughes.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

 Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

 Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026